KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Intangibles (2016 - 2023)

Inovio Pharmaceuticals (INO) has disclosed Intangibles for 14 consecutive years, with $2.0 million as the latest value for Q1 2023.

  • Quarterly Intangibles fell 18.08% to $2.0 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Mar 2023, down 18.08% year-over-year, with the annual reading at $2.1 million for FY2022, 18.9% down from the prior year.
  • Intangibles hit $2.0 million in Q1 2023 for Inovio Pharmaceuticals, down from $2.1 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $4.5 million in Q1 2019 to a low of $2.0 million in Q1 2023.
  • Historically, Intangibles has averaged $3.1 million across 5 years, with a median of $3.0 million in 2021.
  • Biggest five-year swings in Intangibles: dropped 22.4% in 2019 and later fell 14.81% in 2020.
  • Year by year, Intangibles stood at $3.7 million in 2019, then fell by 14.81% to $3.1 million in 2020, then fell by 16.54% to $2.6 million in 2021, then decreased by 18.9% to $2.1 million in 2022, then dropped by 3.85% to $2.0 million in 2023.
  • Business Quant data shows Intangibles for INO at $2.0 million in Q1 2023, $2.1 million in Q4 2022, and $2.2 million in Q3 2022.